Cancers, Vol. 12, Pages 1902: ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Cancers, Vol. 12, Pages 1902: ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Cancers doi: 10.3390/cancers12071902
Authors:
Gaia Griguolo
Fara Brasó-Maristany
Blanca González-Farré
Tomás Pascual
Núria Chic
Tamara SaurÃ
Ronald Kates
Oleg Gluz
Débora MartÃnez
Laia Paré
Vassilena Tsvetkova
David Pesantez
Maria Vidal
Barbara Adamo
Montserrat Muñoz
Patricia Galván
Laura Barberá
Miriam Cuatrecasas
Mathias Christgen
Hans Kreipe
Inés Monge-EscartÃn
Patricia Villagrasa
Dolors Soy
Tommaso Giarratano
Maria Vittoria Dieci
Pierfranco Conte
Nadia Harbeck
Valentina Guarneri
Aleix Prat
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II t...
Source: Cancers - Category: Cancer & Oncology Authors: Gaia Griguolo Fara Bras ó-Maristany Blanca Gonz ález-Farré Tom ás Pascual N úria Chic Tamara Saur à Ronald Kates Oleg Gluz D ébora MartÃnez Laia Par é Vassilena Tsvetkova David Pesantez Maria Vidal Barbara Adamo Montserrat Mu ñoz Patricia Galv à Tags: Article Source Type: research
More News: Adenocarcinoma | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Cervical Cancer | Clinical Trials | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Germany Health | HER2 | Herceptin | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study